Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Cancer development is influenced by diet, environment, and genetics.
• Chemotherapy and radiotherapy face challenges like drug resistance and side effects.
• Apoptotic cells increase in the tumor microenvironment (TME) after conventional treatments.

Purpose of the Study:

• To review the molecular mechanisms of efferocytosis in cancer.
• To outline current therapeutic strategies targeting efferocytosis for cancer treatment.
• To highlight the potential of inhibiting efferocytosis for improved anti-tumor immunity.

Main Methods:

• Review of existing literature on efferocytosis and cancer therapy.
• Analysis of molecular pathways involved in efferocytosis.
• Summary of clinical trials involving efferocytosis inhibitors.

Main Results:

• Excessive efferocytosis can create an immunosuppressive TME, hindering tumor therapy.
• Inhibiting efferocytosis promotes an immune-supportive TME, enhancing treatment efficacy.
• Small-molecule inhibitors and monoclonal antibodies targeting efferocytosis are under clinical investigation.

Conclusions:

• Targeting efferocytosis presents a promising new avenue for cancer treatment.
• Modulating efferocytosis can overcome resistance to existing therapies.
• Further research into efferocytosis mechanisms will drive the development of novel cancer drugs.